Lantheus and GE HealthCare Sign Exclusive Licensing Agreement for Prostate Cancer Imaging Agent in Japan
Reuters
Sep 24, 2025
Lantheus and GE HealthCare Sign Exclusive Licensing Agreement for Prostate Cancer Imaging Agent in Japan
Lantheus Holdings Inc. has announced an exclusive licensing agreement with GE HealthCare for the development, manufacturing, and commercialization of Lantheus' prostate cancer imaging agent, piflufolastat F18, known as PYLARIFY® in the U.S. market, in Japan. This collaboration aims to expand the availability of targeted PET imaging agents for prostate cancer diagnostics and companion diagnostic use in Japan. As part of the agreement, GE HealthCare will pay Lantheus an upfront license fee, development milestones, and tiered royalties based on product sales in Japan. A Joint Steering Committee will be established to oversee development and commercialization activities. The initiative addresses a critical clinical need in Japan, a country with the third highest number of prostate cancer cases globally, and is expected to enhance the detection and care of prostate cancer in the region.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9533989-en) on September 24, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.